[The effect of PSMA PET/CT performed in primary staging on the clinical decision].

Magyar onkologia Pub Date : 2025-07-11 Epub Date: 2024-11-18

Zsófia Küronya, Péter Ágoston, Kliton Jorgo, László Gesztesi, Bence Kapuvári, Péter Dombovári, Stelios Mavrogenis, Lajos Géczi, Enikő Lénárt, Tamás Dienes, Sándor Manninger, Szabolcs Szakáll, Tamás Martin, Krisztina Biró

{"title":"[The effect of PSMA PET/CT performed in primary staging on the clinical decision].","authors":"Zsófia Küronya, Péter Ágoston, Kliton Jorgo, László Gesztesi, Bence Kapuvári, Péter Dombovári, Stelios Mavrogenis, Lajos Géczi, Enikő Lénárt, Tamás Dienes, Sándor Manninger, Szabolcs Szakáll, Tamás Martin, Krisztina Biró","doi":"","DOIUrl":null,"url":null,"abstract":"Aim: Our study aimed to conduct a retrospective statistical analysis of 18F-JK-PSMA-7 PET/CT results in high-risk prostate cancer patients as part of primary staging, to assess how these results influenced the original treatment plan.Methods: The study included high-risk prostate adenocarcinoma patients, localized by conventional imaging, who underwent PSMA PET/CT as part of primary staging between 03/01/2020 and 03/01/2022.Results: PSMA PET/CT confirmed distant metastasis in 20 out of 74 patients. Among them, 7 received local treatment due to oligometastatic disease. The remaining 13 patients had distant lymph node metastasis (1 patient), bone metastasis only (2 patients), or both (10 patients). Based on PSMA PET/CT results, these 13 patients received systemic treatment instead of local therapy. No significant statistical correlation was found between PSA levels, ISUP score, and distant metastasis verification.Conclusion: Broader use of PSMA PET/CT in primary staging of high-risk prostate cancer patients could allow for more precise, personalized therapy in the future.","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"69 2","pages":"203-207"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Magyar onkologia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/18 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Our study aimed to conduct a retrospective statistical analysis of 18F-JK-PSMA-7 PET/CT results in high-risk prostate cancer patients as part of primary staging, to assess how these results influenced the original treatment plan.

Methods: The study included high-risk prostate adenocarcinoma patients, localized by conventional imaging, who underwent PSMA PET/CT as part of primary staging between 03/01/2020 and 03/01/2022.

Results: PSMA PET/CT confirmed distant metastasis in 20 out of 74 patients. Among them, 7 received local treatment due to oligometastatic disease. The remaining 13 patients had distant lymph node metastasis (1 patient), bone metastasis only (2 patients), or both (10 patients). Based on PSMA PET/CT results, these 13 patients received systemic treatment instead of local therapy. No significant statistical correlation was found between PSA levels, ISUP score, and distant metastasis verification.

Conclusion: Broader use of PSMA PET/CT in primary staging of high-risk prostate cancer patients could allow for more precise, personalized therapy in the future.

本刊更多论文

[初级分期PSMA PET/CT对临床决策的影响]。

目的：我们的研究旨在对高危前列腺癌患者的18F-JK-PSMA-7 PET/CT结果进行回顾性统计分析，作为初级分期的一部分，以评估这些结果如何影响原治疗计划。方法：该研究纳入了高风险前列腺腺癌患者，这些患者在2020年3月1日至2022年3月1日期间接受了PSMA PET/CT作为初级分期的一部分。结果：74例患者中有20例经PSMA PET/CT证实有远处转移。其中7例因少转移性疾病接受局部治疗。其余13例有远处淋巴结转移（1例），仅骨转移（2例），或两者兼有（10例）。根据PSMA PET/CT结果，这13例患者接受了全身治疗而不是局部治疗。PSA水平、ISUP评分和远处转移验证之间没有明显的统计学相关性。结论：PSMA PET/CT在高危前列腺癌患者的初级分期中的广泛应用，可以在未来实现更精确、更个性化的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Magyar onkologia

自引率

0.00%

发文量